As AZ/Oxford COVID Vaccine Suffers Another Blow, Russia’s Comes In From The Cold
Sputnik V Filed For EMA Rolling Review
Discouraging news for AstraZeneca’s vaccine as another adenovirus-based vaccine, Russia’s Sputnik V, looks to be gaining favor.
You may also be interested in...
India clears Russian vaccine for restricted use, adding a third vaccine to its arsenal in the fight against COVID-19. One local expert highlights the vaccine’s “clever design” amid hopes that it will hold good against variants as well.
While speculation mounts about Serum Institute being next in line for an RDIF partnership, Gland Pharma and Strides unit Stelis sign up to make COVID-19 vaccine Sputnik V. Part of the 550 million dose output tied up from India so far could be consumed domestically, but exports are a possibility as demand from European countries is set to jump.
South Africa recently decided against using AstraZeneca partner Serum Institute’s vaccine for its immunization program, given its low efficacy against the B.1.351 strain. However, certain vaccines have shown higher efficacy. Is this a sign that newer strains of SARS-CoV-2 could upset supply deals and revenue projections for some vaccines?